Bio-Rad Labs soars after significant earnings beat

Published 31/07/2025, 21:44
Bio-Rad Labs soars after significant earnings beat

Investing.com -- Bio-Rad Laboratories, Inc. (NYSE:BIO) shares surged 12.7% after the life science research and clinical diagnostics company reported second quarter earnings that substantially exceeded analyst expectations, driven by stronger-than-anticipated revenue and improved operating margin guidance.

The company reported adjusted earnings per share of $2.61 for the second quarter, significantly outpacing the analyst estimate of $1.73. Revenue came in at $651.6 million, beating the consensus estimate of $615.2 million and representing a 2.1% increase compared to $638.5 million in the same quarter last year. On a currency-neutral basis, quarterly sales increased 1.0% YoY.

"In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management," said Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer.

The Life Science segment led growth with sales of $262.8 million, up 4.9% compared to the same period in 2024, driven by increased process chromatography and food safety product sales. The Clinical Diagnostics segment reported sales of $388.8 million, essentially flat compared to the prior year.

Bio-Rad also raised its full-year 2025 outlook, now expecting non-GAAP currency-neutral revenue growth of approximately 0 to 1.0%, compared to its previous guidance range of a 1.0% decline to 1.5% growth. The company also increased its non-GAAP operating margin forecast to 12.0-13.0%, up from its prior expectation of 10.0-12.0%.

The company recently completed the acquisition of droplet digital PCR developer Stilla Technologies, expanding its Droplet Digital PCR offering with the launch of its QX Continuum system complemented by the acquired QX700 series of instruments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.